Muscle mass, not radiodensity, predicts physical function in cancer patients with or without cachexia.
cancer cachexia
computed tomography
muscle radiodensity
physical function
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
19 May 2020
19 May 2020
Historique:
received:
24
02
2020
accepted:
27
04
2020
entrez:
6
6
2020
pubmed:
6
6
2020
medline:
6
6
2020
Statut:
epublish
Résumé
There is a need to better understand the relationship between functional impairment and muscle mass in cancer cachexia. This study aimed to establish the relationship between computed tomography (CT)-derived muscle cross-sectional area (CSA), radiodensity, and skeletal muscle index (SMI) and dual energy X-ray absorptiometry (DXA) parameters with functional performance in cancer patients. Handgrip strength, stair climb power (SCP), one-repetition maximum (1RM) strength, and body composition (CT and DXA) were compared across cancer patients with cachexia (CAC; CAC had lower CT muscle CSA and SMI and lower DXA appendicular lean mass (ALM) than CNC or CON ( Stair climb power was reduced in cancer cachexia; muscle radiodensity was not. Muscle mass by CT or DXA, but not radiodensity, predicted functional performance in cancer patients.
Sections du résumé
BACKGROUND
BACKGROUND
There is a need to better understand the relationship between functional impairment and muscle mass in cancer cachexia. This study aimed to establish the relationship between computed tomography (CT)-derived muscle cross-sectional area (CSA), radiodensity, and skeletal muscle index (SMI) and dual energy X-ray absorptiometry (DXA) parameters with functional performance in cancer patients.
MATERIALS AND METHODS
METHODS
Handgrip strength, stair climb power (SCP), one-repetition maximum (1RM) strength, and body composition (CT and DXA) were compared across cancer patients with cachexia (CAC;
RESULTS
RESULTS
CAC had lower CT muscle CSA and SMI and lower DXA appendicular lean mass (ALM) than CNC or CON (
CONCLUSIONS
CONCLUSIONS
Stair climb power was reduced in cancer cachexia; muscle radiodensity was not. Muscle mass by CT or DXA, but not radiodensity, predicted functional performance in cancer patients.
Identifiants
pubmed: 32499874
doi: 10.18632/oncotarget.27594
pii: 27594
pmc: PMC7244015
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1911-1921Subventions
Organisme : NIDDK NIH HHS
ID : T32 DK007247
Pays : United States
Organisme : BLRD VA
ID : I01 BX002807
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK035816
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG061558
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK017047
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA239208
Pays : United States
Organisme : NIA NIH HHS
ID : T35 AG026736
Pays : United States
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST These authors report no conflicts of interest.
Références
Support Care Cancer. 2016 Aug;24(8):3473-80
pubmed: 27003901
Lancet Oncol. 2011 May;12(5):489-95
pubmed: 21296615
Arch Phys Med Rehabil. 2018 Dec;99(12):2595-2620
pubmed: 29738745
J Appl Physiol (1985). 2001 Jun;90(6):2157-65
pubmed: 11356778
Am J Epidemiol. 1998 Apr 15;147(8):755-63
pubmed: 9554417
J Appl Physiol (1985). 2004 Dec;97(6):2333-8
pubmed: 15310748
J Cachexia Sarcopenia Muscle. 2015 Dec;6(4):272-4
pubmed: 26675232
PLoS One. 2018 Oct 2;13(10):e0204529
pubmed: 30278056
Oncotarget. 2017 May 16;8(20):33658-33665
pubmed: 28431396
Langenbecks Arch Surg. 2014 Mar;399(3):287-95
pubmed: 24535479
Lancet Oncol. 2015 Jan;16(1):108-16
pubmed: 25524795
Exp Gerontol. 2019 Oct 1;125:110688
pubmed: 31404625
Ann Palliat Med. 2019 Jan;8(1):24-32
pubmed: 30525765
Ann Palliat Med. 2019 Jan;8(1):3-12
pubmed: 30685982
Nutr Metab Cardiovasc Dis. 2013 Dec;23 Suppl 1:S19-24
pubmed: 22749678
J Gerontol A Biol Sci Med Sci. 2006 Oct;61(10):1059-64
pubmed: 17077199
Eur Urol Focus. 2018 Apr;4(3):420-434
pubmed: 28753824
J Cachexia Sarcopenia Muscle. 2019 Apr;10(2):445-454
pubmed: 30924270
Oncologist. 2010;15(2):200-11
pubmed: 20156909
J Clin Endocrinol Metab. 2012 May;97(5):E700-9
pubmed: 22419719
Appl Physiol Nutr Metab. 2008 Oct;33(5):997-1006
pubmed: 18923576
Clin Nutr. 2019 Dec;38(6):2875-2880
pubmed: 30612853
J Orthop Translat. 2018 Oct 28;15:91-103
pubmed: 30533385
J Geriatr Oncol. 2019 May;10(3):415-419
pubmed: 30196027
PLoS One. 2015 Oct 12;10(10):e0140403
pubmed: 26457674
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
J Appl Physiol (1985). 1998 Jul;85(1):115-22
pubmed: 9655763
J Cachexia Sarcopenia Muscle. 2019 Dec;10(6):1356-1377
pubmed: 31307124
JPEN J Parenter Enteral Nutr. 2018 Sep;42(7):1148-1155
pubmed: 29350403
Clin Nutr. 2012 Apr;31(2):176-82
pubmed: 22047681
J Clin Oncol. 2013 Apr 20;31(12):1539-47
pubmed: 23530101
Ann Palliat Med. 2019 Jan;8(1):43-49
pubmed: 30685983
Ann Oncol. 2017 Aug 1;28(8):1949-1956
pubmed: 28472437
J Clin Endocrinol Metab. 1999 Oct;84(10):3420-30
pubmed: 10522974
Acta Physiol (Oxf). 2014 Mar;210(3):489-97
pubmed: 24393306
Lancet Oncol. 2013 Apr;14(4):335-45
pubmed: 23499390
Lancet Oncol. 2016 Apr;17(4):519-531
pubmed: 26906526
Sports Med. 1987 Jul-Aug;4(4):268-89
pubmed: 3306867
BMC Geriatr. 2016 Oct 5;16(1):170
pubmed: 27716195
J Cachexia Sarcopenia Muscle. 2019 Feb;10(1):22-34
pubmed: 30920776
J Gerontol A Biol Sci Med Sci. 2019 Sep 15;74(10):1671-1678
pubmed: 30726878
Am J Clin Nutr. 2006 Jun;83(6):1345-50
pubmed: 16762946
J Cachexia Sarcopenia Muscle. 2017 Oct;8(5):759-767
pubmed: 28493418